Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.

André von Bueren; M D Bacolod; Christian Hagel; K Heinimann; A Fedier; Uwe Kordes; T Pietsch; J Koster; M A Grotzer; H S Friedman; G Marra; M Kool; Stefan Rutkowski

doi:10.1038/bjc.2012.403

Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumours.

André von Bueren
M D Bacolod
Christian Hagel
K Heinimann
A Fedier
Uwe Kordes
T Pietsch
J Koster
M A Grotzer
H S Friedman
G Marra
M Kool
Stefan Rutkowski

Related Research units

Department of Pediatric Hematology and Oncology
Institute of Neuropathology

Abstract

Tumours are responsive to temozolomide (TMZ) if they are deficient in O(6)-methylguanine-DNA methyltransferase (MGMT), and mismatch repair (MMR) proficient.

Bibliographical data

Original language	English
Article number	8
ISSN	0007-0920
DOIs	https://doi.org/10.1038/bjc.2012.403
Publication status	Published - 09.10.2012